1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
- Read more in our News Archive
Current Studies at Motherisk
Diclegis Surveillance Program Study
Diclectin Surveillance Program Study
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Environmental Exposures and Children's Health
Alcohol Use during Pregnancy
Control of Hypertension in Pregnancy Study
Folic Acid Before and During Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
Treatment of heartburn and acid reflux associated with nausea and vomiting during pregnancy
Ruth Law, Caroline Maltepe, Pina Bozzo and Adrienne Einarson, RN
In addition to suffering from nausea and vomiting of pregnancy, which is being treated with antiemetics, some of my pregnant patients complain of heartburn and acid reflux. Should these symptoms also be treated and, if so, which acid-reducing medications are safe for use during pregnancy?
Increased severity of nausea and vomiting of pregnancy is associated with the presence of heartburn and acid reflux. Antacids, histamine-2 receptor antagonists, and proton pump inhibitors can be used safely during pregnancy, as large studies have been published with no evidence of adverse fetal effects.
En plus de souffrir de la nausée et des vomissements de la grossesse, des malaises traités à l'aide d'antiémétiques, certaines de mes patientes enceintes se plaignent de brûlures d'estomac et de reflux acides. Devrait-on aussi traiter ces symptômes et, dans l'affirmative, quels sont les médicaments contre l'hyperacidité qui sont sans risque durant la grossesse?
La gravité accrue de la nausée et des vomissements est associée à la présence de brûlures d'estomac et de reflux acides. Les antiacides, les antagonistes du récepteur H2 de l'histamine et les inhibiteurs de la pompe à protons peuvent être utilisés en toute sécurité durant la grossesse, puis que d'importantes études publiées ne révèlent pas de données factuelles à l'effet qu'ils causeraient des effets indésirables chez le ftus
Gastroesophageal reflux disease (GERD) is reported in up to 80% of pregnancies.1 It is likely caused by a reduction in lower esophageal sphincter pressure due to an increase in maternal estrogen and progesterone during pregnancy. Hormonal changes in pregnancy can also decrease gastric motility, resulting in prolonged gastric emptying time and increased risk of GERD.1 The most common symptoms of GERD are heartburn and acid reflux. Treatment algorithms suggest stepwise progression of options, starting with lifestyle modifications (eg, eat smaller and more frequent meals, avoid eating near bedtime, elevate the head of the bed) and trying pharmacologic therapy if symptoms are not adequately managed by lifestyle changes.1
Safety of acid-reducing agents
Antacids containing aluminum, calcium, and magnesium were not found to be teratogenic in animal studies and are recommended as first-line treatment of heartburn and acid reflux during pregnancy.2 High-dose and prolonged use of magnesium trisilicate is associated with nephrolithiasis, hypotonia, and respiratory distress in the fetus, and its use is not recommended during pregnancy.3 Bicarbonate-containing antacids are also not recommended owing to the risk of maternal and fetal metabolic acidosis and fluid overload.3 There are also case reports of milk-alkali syndrome in pregnant women who used daily doses higher than 1.4 g of elemental calcium obtained from calcium carbonate.4,5
Histamine-2 receptor antagonists (H2RAs)
Cimetidine, ranitidine, famotidine, and nizatidine are the H2RAs approved for use in Canada. Details of studies on the use of each agent during pregnancy were reviewed elsewhere.1 A recent meta-analysis involving 2398 pregnant women exposed to H2RAs in at least the first trimester compared with 119 892 women in the control group showed an odds ratio of 1.14 (95% confidence interval [CI] 0.89 to 1.45) for congenital malformation. There was no statistically significant difference in risk of spontaneous abortion or preterm delivery between the exposed women and the control group.6
Proton pump inhibitors (PPIs)
Proton pump inhibitors approved by Health Canada include omeprazole, pantoprazole, lansoprazole, esomeprazole, and rabeprazole. Safety of omeprazole, pantoprazole, esomeprazole, and lansoprazole use during pregnancy was reported elsewhere.7 Rabeprazole use in pregnancy has not been studied in humans; however, based on animal data on rabeprazole and human data of other PPIs, it is expected that rabeprazole would be safe for use in pregnancy.8 A recent meta-analysis that compared 1530 pregnant women exposed to PPIs in at least the first trimester with 133 410 unexposed pregnant women showed an odds ratio of 1.12 (95% CI 0.84 to 1.45) for congenital malformation. There was also no statistically significant difference in the odds ratios for spontaneous abortion or preterm delivery between the 2 groups.9
Why treat heartburn and acid reflux during pregnancy?
Heartburn and acid reflux are traditionally considered innocuous because they are common in pregnancy and are usually self-limiting. However, a recent study suggests that GERD is associated with an increase in the severity of nausea and vomiting of pregnancy (NVP), which can have serious negative effects on a womans quality of life.10 In a prospective cohort study conducted by the Motherisk Program, 194 pregnant women with NVP and heartburn or acid reflux were compared with 188 pregnant women with NVP who did not have heartburn or acid reflux. The 2 groups were assessed for severity of NVP with the pregnancy-unique quantification of emesis and nausea (PUQE) score, which is a validated scoring tool based on frequency and duration of nausea, vomiting, and retching in the past 24 hours, with a high score indicating more severe NVP. Quality of life was measured by the well-being score, with 0 being the worst and 10 being the best. Forty-eight percent of women in the control group had severe NVP according to the PUQE, compared with 75% in the group with heartburn and acid reflux. The mean well-being score in the control group was significantly higher than that in the group with heartburn and acid reflux (4.9 SD [2.0] vs 3.9 [SD 2.1]; P = .0004).11
Another prospective study also conducted by the Motherisk Program investigated the relationship between the use of acid-reducing medication and severity of NVP in 60 pregnant women. These women were counseled to continue their current antiemetics and to start acid-reducing agents; the PUQE and well-being scoring tools were administered before the start of acid-reducing therapy and at follow-up. The use of acid-reducing therapy was associated with a reduction in PUQE score (9.6 [SD 3.0] to 6.5 [SD 2.5]; P < .0001) and an increase in the well-being score (4.0 [SD 2.0] to 6.8 [SD 1.6]; P < .0001).12 The results of these 2 studies suggest that treatment of heartburn and acid reflux is associated with improvement in NVP and quality of life.
Heartburn, and acid reflux during pregnancy should be treated, as recent studies report that symptoms of GERD have been associated with an increased severity of pregnancy-related nausea and vomiting. Antacids, H2RAs, and PPIs are safe for use in pregnancy, so if life-style modifications fail to manage GERD symptoms, these medications can be added to the antiemetic treatment regimen. Physicians should always feel comfortable treating NVP aggressively, so as to improve the quality of life of pregnant women.
Motherisk questions are prepared by the Motherisk Team at The Hospital for Sick Children in Toronto, Ont. Drs. Staroselsky, Klieger-Grossmann, and Garcia-Bournissen are members and Dr. Koren is Director of the Motherisk Program. Dr. Koren is supported by the Research Leadership for Better Pharmacotherapy during Pregnancy and Lactation. He holds the Ivey Chair in Molecular Toxicology in the Department of Medicine at the University of Western Ontario in London.
Can Fam Physician
Vol. 56, No. 2, January 2010, pp.143 - 144
Copyright ©2010 by The College of Family Physicians of Canada
- Ali RA, Egan LJ. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol 2007;21(5):793–806.[Medline]
- Mahadevan U, Kane S. American Gastroenterological Association Institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006;131(1):278–82.[Medline]
- Mahadevan U. Gastrointestinal medications in pregnancy. Best Pract Res Clin Gastroenterol 2007;21(5):849–77.[Medline]
- McGuinness B, Logan JI. Milk alkali syndrome. Ulster Med J 2002;71(2):132–5.[Medline]
- Gordon MV, McMahon LP, Hamblin PS. Life-threatening milk-alkali syndrome resulting from antacid ingestion during pregnancy. Med J Aust 2005;182(7):350–1.[Medline]
- Gill SK, OBrien L, Koren G. The safety of histamine 2 (H2) blockers in pregnancy: a meta-analysis. Dig Dis Sci 2009;54(9):1835–8. Epub 2008 Dec 3.[Medline]
- Nava-Ocampo AA, Valázquez-Armenta EY, Han JY, Koren G. Use of proton pump inhibitors during pregnancy and breastfeeding. Can Fam Physician 2006;52:853–4.
[Abstract/Free Full Text]
- Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther 2005;22(9):749–57.[Medline]
- Gill SK, OBrien L, Einarson TR, Gideon K. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104(6):1541–5. Epub 2009 Apr 28.[Medline]
- Attard CL, Kohli M, Coleman S, Bradley C, Hux M, Atanackovic G, et al. The burden of illness of severe nausea and vomiting of pregnancy in the United States. Am J Obstet Gynecol 2002;186(Suppl_5):S220–7.[Medline]
- Gill SK, Maltepe C, Koren G. The effect of heartburn and acid reflux on the severity of nausea and vomiting of pregnancy. Can J Gastroenterol 2009;23(4):270–2.[Medline]
- Gill SK, Maltepe C, Mastali K, Koren G. The effect of acid-reducing pharmacotherapy on the severity of nausea and vomiting of pregnancy. Obstet Gynecol Int 2009, 10.1155/2009/585269.